Skip to main content

BLTE · Belite Bio, Inc · Webcasts, Transcripts & Audio

Track BLTE — free
$127.38 -23.64 (-15.65%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$5.17B
Shares
40.61M
Volume · Nov 20 1.04M Avg daily vol (3M) 194.38K

Belite Bio, Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Belite Bio, Inc (BLTE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-11-12
Belite Bio, Inc (BLTE) Q3 2026 Earnings Call Transcript
Positive tone International regulatory expansion U.S. regulatory review Losses and increased operating expenses
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-13
Belite Bio, Inc (BLTE) Q2 2026 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-20
Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript
Confident tone NDA submission and FDA approval timeline Financial position and operating expenses Dragon 2 / Japan registration trial
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
Belite Bio, Inc (BLTE) Q4 2025 Earnings Call Transcript
Confident tone NDA submission and regulatory pathway International/ex-US regulatory strategy and partnering Prevalence and pediatric expansion
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q2
2025-08-11
Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript
Confident tone Tinlarebant clinical progress Geographic atrophy (PHOENIX) trial Commercialization planning
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Date not confirmed
Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript
Confident tone Phase 3 DRAGON (Stargardt) interim results Tinlarebant drug profile and safety PHOENIX Phase 3 trial in geographic atrophy
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Date not confirmed
Belite Bio, Inc (BLTE) Q4 2024 Earnings Call Transcript
Confident tone Phase 3 DRAGON trial in Stargardt disease Enrollment dropout rates Phase 3 PHOENIX trial in GA
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-19
Belite Bio, Inc (BLTE) Q3 2024 Earnings Call Transcript
Confident tone Tinlarebant clinical pipeline progress Phase 2 Stargardt efficacy results Geographic atrophy positioning vs complement inhibitors
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Date not confirmed
Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript
Confident tone Tinlarebant clinical programs Japan regulatory strategy Phase II Stargardt data
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript
Confident tone Stargardt disease Phase 2 data Stargardt Phase 3 (DRAGON) progress Geographic Atrophy (GA) Phase 3
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Date not confirmed
Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Date not confirmed
Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
Belite Bio, Inc (BLTE) Q2 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Date not confirmed
Belite Bio, Inc (BLTE) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Date not confirmed
Belite Bio, Inc (BLTE) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
Belite Bio, Inc (BLTE) Q2 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–16 of 16 webcasts
Key facts CIK 1889109 CUSIP 07782B104 13F (30d) 94 filings 93 filers Visit website Investor relations